SCHEMBL1711263

SCHEMBL1711263

CC(=O)Oc1ccccc1/C=C/C(=O)O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.63
GAA P10253 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.57
KDM4E B2RXH2 4/20 0.56
PTGER1 P34995 1/20 0.55
PTGER4 P35408 1/20 0.55
PTGER3 P43115 1/20 0.55
PTGER2 P43116 1/20 0.55
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
NFKB1 P19838 1/20 0.53
CA4 P22748 1/20 0.53
NFE2L2 Q16236 2/20 0.53
TFEB P19484 1/20 0.53
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
HSP90AA1 P07900 1/20 0.52
TDP1 Q9NUW8 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1711265 1.00 HTT (0.63) HTTGAASMN1; SMN2KDM4EPTGER1
SCHEMBL4715093 1.00 HTT (0.63) HTTGAASMN1; SMN2KDM4EPTGER1
SCHEMBL13036867 0.88 NFE2L2 (0.69) HTTKDM4EMEN1KMT2ANFKB1
SCHEMBL20110943 0.88 KDM4E (0.72) HTTKDM4EMEN1KMT2ANFE2L2
SCHEMBL1603612 0.87 MEN1 (0.60) SMN1; SMN2KDM4EMEN1KMT2ANFKB1
SCHEMBL16498326 0.85 MAPT (0.72) HTTSMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL16498329 0.85 MAPT (0.72) HTTSMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL17305571 0.85 KDM4E (0.54) HTTGAAKDM4EMEN1KMT2A
SCHEMBL4712845 0.85 KDM4E (0.54) HTTGAASMN1; SMN2KDM4EMEN1
SCHEMBL18121457 0.85 KDM4E (0.54) HTTGAAKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0153538-B1 DERIVATIVES OF MELILOTIC ACID, AND MEDICAMENTS CONTAINING THEM Laboratoire Marcel Richard Société anonyme dite (FR) 1986-11-26 EP claimed
JP-63039847-A None JP disclosed
CN-116003710-B Polyacrylic polymer modified substrate, preparation method thereof and application thereof in preparation of biochip 中国海洋大学 2025-04-08 CN disclosed
CN-119193555-A Ferulic acid decarboxylase high-activity mutant and application thereof 大连理工大学 2024-12-27 CN disclosed
CN-118086266-B Ferulic acid decarboxylase high-activity combined mutant and application thereof 大连理工大学 2024-10-25 CN disclosed
CN-118086266-A Ferulic acid decarboxylase high-activity combined mutant and application thereof 大连理工大学 2024-05-28 CN disclosed
US-11873354-B2 Photobase generator, compound, photoreactive composition, and reaction product TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) 2024-01-16 US disclosed
CN-116003710-A Polyacrylic polymer modified substrate, preparation method thereof and application thereof in preparation of biochip 中国海洋大学 2023-04-25 CN disclosed
US-20210214374-A1 COMPOUNDS AND COMPOSITIONS FOR OCULAR DELIVERY Graybug Vision, Inc. (US) 2021-07-15 US disclosed
US-20210214374-A1 COMPOUNDS AND COMPOSITIONS FOR OCULAR DELIVERY Graybug Vision, Inc. (US) 2021-07-15 US disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP disclosed
EP-1049682-A1 OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION Versicor, Inc. (US) 2000-11-08 EP disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 WO disclosed
WO-1999037630-A1 OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION VERSICOR, INC. (US) 1999-07-29 WO disclosed
US-5599478-A Compensator for a liquid crystal display NIPPON OIL COMPANY, LIMITED (JP) 1997-02-04 US disclosed
EP-0702260-A1 Compensator for a liquid crystal display NIPPON OIL CO. LTD. (JP) 1996-03-20 EP disclosed
EP-0656927-A1 METALLO ORGANO LIQUID CRYSTALS IN A POLYMER MATRIX Sniaricerche S.C.P.A. (IT) 1995-06-14 EP disclosed
EP-0343714-B1 Phenylglycidate stereoisomers, conversion products thereof with e.g. 2-nitrothiophenol and preparation of diltiazem DSM NV (NL) 1994-11-02 EP disclosed
EP-0343714-A1 Phenylglycidate stereoisomers, conversion products thereof with e.g. 2-nitrothiophenol and preparation of diltiazem DSM N.V. (NL) 1989-11-29 EP disclosed
JP-S6339847-A P-HYDROXYCINNAMAMIDE DERIVATIVE AND MELANIN SUPPRESSIVE AGENT CONTAINING SAME KAO CORP 1988-02-20 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873354-B2 Photobase generator, compound, photoreactive composition, and reaction product GNB1, GNAQ, GNG2 HTT 4751/4885GAA 1661/4885SMN1; SMN2 4542/4885
US-20210214374-A1 COMPOUNDS AND COMPOSITIONS FOR OCULAR DELIVERY KDR, RB1, PDE6C HTT 1142/4885GAA 892/4885SMN1; SMN2 700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.